Cargando…

Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer

INTRODUCTION: Lymphocyte‐to‐monocyte ratio (LMR) has been reported as a prognostic factor in many cancers but the data are to date limited for its use in oral cavity cancer. The purpose of this study was to evaluate the prognostic value of LMR in advanced‐stage oral cavity cancer. METHODS: Data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Supanimitjaroenporn, Pasawat, Kirtsreesakul, Virat, Tangthongkum, Manupol, Leelasawatsuk, Peesit, Prapaisit, Usaporn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194982/
https://www.ncbi.nlm.nih.gov/pubmed/35734053
http://dx.doi.org/10.1002/lio2.790
_version_ 1784726865261363200
author Supanimitjaroenporn, Pasawat
Kirtsreesakul, Virat
Tangthongkum, Manupol
Leelasawatsuk, Peesit
Prapaisit, Usaporn
author_facet Supanimitjaroenporn, Pasawat
Kirtsreesakul, Virat
Tangthongkum, Manupol
Leelasawatsuk, Peesit
Prapaisit, Usaporn
author_sort Supanimitjaroenporn, Pasawat
collection PubMed
description INTRODUCTION: Lymphocyte‐to‐monocyte ratio (LMR) has been reported as a prognostic factor in many cancers but the data are to date limited for its use in oral cavity cancer. The purpose of this study was to evaluate the prognostic value of LMR in advanced‐stage oral cavity cancer. METHODS: Data from 211 advanced‐stage oral cancer patients treated with curative intent between January 2009 and December 2015 were obtained from the hospital information system. Pretreatment LMR and other hematologic parameters were recorded and an LMR cutoff value was calculated. Overall survival between the groups above (high LMR) and below (low LMR) the cutoff was compared and hazard ratios from univariate and multivariate analyses using a Cox proportional hazards model calculated. RESULTS: Overall survival and disease‐specific survival were better in the high LMR group. The 5‐year overall survival rates were 31.6% and 15% in the high LMR and low LMR groups, respectively. Multivariate analysis using a Cox proportional hazards model showed that treatment modality and LMR were the only factors associated with overall survival. CONCLUSION: Low LMR was associated with poor survival outcome in patients with advanced‐stage oral cavity cancer. LEVEL OF EVIDENCE: 2b.
format Online
Article
Text
id pubmed-9194982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-91949822022-06-21 Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer Supanimitjaroenporn, Pasawat Kirtsreesakul, Virat Tangthongkum, Manupol Leelasawatsuk, Peesit Prapaisit, Usaporn Laryngoscope Investig Otolaryngol Head and Neck, and Tumor Biology INTRODUCTION: Lymphocyte‐to‐monocyte ratio (LMR) has been reported as a prognostic factor in many cancers but the data are to date limited for its use in oral cavity cancer. The purpose of this study was to evaluate the prognostic value of LMR in advanced‐stage oral cavity cancer. METHODS: Data from 211 advanced‐stage oral cancer patients treated with curative intent between January 2009 and December 2015 were obtained from the hospital information system. Pretreatment LMR and other hematologic parameters were recorded and an LMR cutoff value was calculated. Overall survival between the groups above (high LMR) and below (low LMR) the cutoff was compared and hazard ratios from univariate and multivariate analyses using a Cox proportional hazards model calculated. RESULTS: Overall survival and disease‐specific survival were better in the high LMR group. The 5‐year overall survival rates were 31.6% and 15% in the high LMR and low LMR groups, respectively. Multivariate analysis using a Cox proportional hazards model showed that treatment modality and LMR were the only factors associated with overall survival. CONCLUSION: Low LMR was associated with poor survival outcome in patients with advanced‐stage oral cavity cancer. LEVEL OF EVIDENCE: 2b. John Wiley & Sons, Inc. 2022-03-30 /pmc/articles/PMC9194982/ /pubmed/35734053 http://dx.doi.org/10.1002/lio2.790 Text en © 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Head and Neck, and Tumor Biology
Supanimitjaroenporn, Pasawat
Kirtsreesakul, Virat
Tangthongkum, Manupol
Leelasawatsuk, Peesit
Prapaisit, Usaporn
Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
title Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
title_full Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
title_fullStr Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
title_full_unstemmed Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
title_short Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
title_sort prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
topic Head and Neck, and Tumor Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194982/
https://www.ncbi.nlm.nih.gov/pubmed/35734053
http://dx.doi.org/10.1002/lio2.790
work_keys_str_mv AT supanimitjaroenpornpasawat prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer
AT kirtsreesakulvirat prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer
AT tangthongkummanupol prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer
AT leelasawatsukpeesit prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer
AT prapaisitusaporn prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer